



## **Integra LifeSciences Launches Radionics CRW BiopsyPlus Kit**

PLAINSBORO, N.J., Dec 7, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has launched the Radionics CRW(TM) BiopsyPlus Kit, which is designed to simplify the use of the Nashold Biopsy Needle when used with the Radionics CRW(TM) stereotactic system. The new device combines all the accessories for the procedure in a single sterile package and requires no assembly or adjustments.

"Feedback from hundreds of Integra Radionics CRW users worldwide contributed to the development of the Radionics CRW (TM) BiopsyPlus Kit," said Jason D. Ellnor, director of marketing for Integra's stereotactic products. "We designed it to make stereotactic biopsies with the Radionics CRW(TM) system even easier and quicker, while still providing the trusted accuracy for which our products are known."

The disposable side cutting brain biopsy needle was originally developed by the renowned neurosurgeon Blaine S. Nashold, Jr., MD (Professor Emeritus of Surgery, Division of Neurosurgery, Duke University Medical Center) and Eric Cosman, PhD (past-president and former owner of Radionics) in the 1980's to work in conjunction with Radionics industry-leading stereotactic surgery devices. The combination of the Radionics CRW(TM) stereotactic system and the Nashold Biopsy needle has long provided neurosurgeons with the confidence to perform precise and safe brain biopsies.

"Integra's new Radionics CRW(TM) biopsy system simplifies brain biopsies without compromising accuracy or confidence," stated Dr. Allan Friedman, Chief of Neurosurgery at Duke University Medical Center in Durham, North Carolina. "Advances like this enable neurosurgeons to concentrate more attention on the patient."

Approximately 17,000 brain biopsies for cancer patients are performed in the U.S. annually and are vital to determining the appropriate management of a patient's cancer. Stereotactic systems are used when maximum accuracy and minimal collateral involvement are essential.

The Integra NeuroSciences direct sales organization will sell the Radionics CRW(TM) BiopsyPlus Kit. Integra NeuroSciences is a leading provider of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 200 direct sales professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at [www.Integra-LS.com](http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the CRW(TM) BiopsyPlus Kit, Radionics CRW(TM) stereotactic system and the Nashold Biopsy Needle. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

IART-P

This news release was distributed by PrimeNewswire, [www.primenewswire.com](http://www.primenewswire.com)

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President,  
Chief Administrative Officer and Acting Chief Financial Officer  
(609) 936-2481  
[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)

Gianna Sabella, Public Relations Manager  
(609) 936-2389  
[gsabella@integra-LS.com](mailto:gsabella@integra-LS.com)

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX